Abstract:Tumor necrosis factor alpha (TNF-alpha) is overexpressed in various diseases, and it has been a validated therapeutic target for autoimmune diseases. All therapeutics currently used to target TNF-alpha are biomacromolecules, limited numbers of TNF-alpha chemical inhibitors have been reported, which makes the identification of small-molecule alternatives an urgent need. Recent studies have mainly focused on identifying small molecules that directly bind to TNF-alpha or TNF receptor-1 (TNFR1), inhibit the interaction between TNF-alpha and TNFR1, and/or regulate related signaling pathways. In this study, we combined in silico methods with biophysical and cell-based assays to identify novel antagonists that bind to TNF-alpha or TNFR1. Pharmacophore model filtering and molecular docking were applied to identify potential TNF-alpha antagonists. In regard to TNFR1, we constructed a threedimensional model of the TNF-alpha TNFR1 complex and carried out molecular dynamics simulations to sample the conformations. The residues in TNF-alpha that have been reported to play important roles in the TNF-alpha TNFR1 complex were removed to form a pocket for further virtual screening of TNFR1-binding ligands. We obtained 20 virtual hits and tested them using surface plasmon resonance-based assays, which resulted in one ligand that binds to TNFR1 and four ligands with different scaffolds that bind to TNF-alpha. T1 and R1, the two most active compounds with Kd values of H and 16 uM for TNF-alpha and TNFR1, respectively, showed activities similar to those of known antagonists. Further cell-based assays also demonstrated that T1 and R1 have similar activities compared to the known TNF-alpha antagonist C87. Our work has not only produced several TNF-alpha and TNFR1 antagonists with novel scaffolds for further structural optimization but also showcases the power of our in silico methods for TNF-alpha- and TNFR1-based drug discovery.

Ligand-based pharmacophore modeling, virtual screening and biological evaluation to identify novel TGR5 agonists

Pharmacophore modeling and virtual screening studies for discovery of novel farnesoid X receptor (FXR) agonists

Discovery and characterization of small-molecule TGR5 ligands with agonistic activity

Design, synthesis and biological evaluations of novel farnesoid X receptor (FXR) agonists

Design, synthesis, and structure-activity relationships of 3,4,5-trisubstituted 4,5-dihydro-1,2,4-oxadiazoles as TGR5 agonists.

Identification of Novel TRPC5 Inhibitors by Pharmacophore-Based and Structure-Based Approaches

Design, synthesis and evaluation of 3-phenoxypyrazine-2-carboxamide derivatives as potent TGR5 agonists

Molecular Docking and Molecular Dynamics Simulation Studies of GPR40 Receptor–agonist Interactions

Design, synthesis and evaluation of 1-benzyl-1H-imidazole-5-carboxamide derivatives as potent TGR5 agonists

Molecular Modeling of the 3D Structure of 5-HT(1A)R: Discovery of Novel 5-HT(1A)R Agonists Via Dynamic Pharmacophore-Based Virtual Screening.

Toll-like Receptor 7 Agonists: Chemical Feature Based Pharmacophore Identification and Molecular Docking Studies.

Update on the development of TGR5 agonists for human diseases

Three-Dimensional Pharmacophore Modeling of Liver-X Receptor Agonists

Discovery of novel modulators targeting human TRPC5: Docking-based virtual screening, molecular dynamics simulation and binding affinity predication

Identification of potential drug candidates as TGR5 agonist to combat type II diabetes using in silico docking and molecular dynamics simulation studies

Insights into the discovery of new 5-HT1A receptor ligands:receptor based pharmacophore

Design, Synthesis, and Biological Evaluation of Covalently Mucoadhesive Derivatives as Nonsystemic Intestine-Targeted TGR5 Agonists

Recent Advances in the Drug Discovery and Development of Dualsteric/ Bitopic Activators of G Protein-Coupled Receptors.

Discovery of novel TRPV1 modulators through machine learning‐based molecular docking and molecular similarity searching

Discovery of Novel Ligands for TNF-α and TNF Receptor-1 Through Structure-Based Virtual Screening and Biological Assay

Discovery of Novel Allosteric Modulators Targeting an Extra-Helical Binding Site of GLP-1R Using Structure- and Ligand-Based Virtual Screening